Global
吉凯基因 新药研发
吉凯基因 新药研发

新药研发聚焦于细胞治疗、基因治疗、抗体药物等创新药物的开发,致力于与临床医生共同将具有重大临床意义的科学研究进行临床转化,开发能够解决临床迫切需求的治疗产品。

目前已经建立起包含CAR-T、TCR-T等细胞治疗项目,AAV基因治疗项目以及单克隆抗体项目在内的完整的开发管线,并与多名领域带头人签署了长期的深度合作协议。

研发管线

Cell Therapy Target Validation Lead Candidate Clinical Study
CD19 GB5005 Leukemia CAR-T

Phase:Clinical Study
BCMA GB5010 Multiple Melanoma CAR-T

Phase:Clinical Study
GPC3 GB5011 Liver Cancer CAR-T

Phase:Clinical Study
CEACAM5 GB5012 Colon Cancer CAR-T

Phase:Clinical Study
MG7 GB70015 Gastric Cancer (FIC) CAR-T

Phase:Clinical Study
Claudin 18.2 GB70041 Gastric Cancer CAR-T

Phase:Candidate
NY-ESO-1 GB3007 Synovial Sarcoma TCR-T

Phase:Candidate
RASm GB3010 Pancreatic Cancer (FIC) TCR-T

Phase:Lead
EBV GB3015 Nasopharyngeal Carcinoma TCR-T

Phase:Lead
Therapeatic Antibody Target Validation Lead Candidate Clinical Study
Claudin 18.2 GB7004 Gastric Cancer mAb

Phase:Candidate
MG7 GB7001 Gastric Cancer (FIC) mAb

Phase:Candidate
CD73 GB7002 Solid Tumor mAb

Phase:Candidate
CEACAM5 GB7012 Colon Cancer mAb

Phase:Candidate
PD-L1 GB7003 Solid Tumor mAb

Phase:Candidate
CD47 GB7005 Solid Tumor mAb

Phase:Candidate
NY-ESO-1 GB7007 Sarcoma (FIC) mAb

Phase:Lead
Claudin 6 GB7008 Ovarian Cancer mAb

Phase:Lead

合作伙伴